Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 17/20 | 0.86 |
| ▸ | KDM1A | O60341 | 2/20 | 0.62 |
| ▸ | MAOA | P21397 | 2/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483190 | 1.00 | TACR1 (0.86) | TACR1KDM1AMAOAMAOBCYP2D6 | |
| SCHEMBL4483185 | 1.00 | TACR1 (0.86) | TACR1KDM1AMAOAMAOBCYP2D6 | |
| SCHEMBL4938649 | 1.00 | TACR1 (0.86) | TACR1KDM1AMAOAMAOBCYP2D6 | |
| SCHEMBL4938640 | 1.00 | TACR1 (0.86) | TACR1KDM1AMAOAMAOBCYP2D6 | |
| Hydrochloric Acid SCHEMBL4938654 | 0.99 | TACR1 (0.84) | TACR1KDM1AMAOAMAOBCYP2D6 | |
| Hydrochloric Acid SCHEMBL4938659 | 0.99 | TACR1 (0.84) | TACR1KDM1AMAOAMAOBCYP2D6 | |
| Hydrochloric Acid SCHEMBL4938665 | 0.99 | TACR1 (0.84) | TACR1KDM1AMAOAMAOBCYP2D6 | |
| Cp-99994 SCHEMBL3951615 | 0.93 | TACR1 (1.00) | TACR1CYP2D6 | |
| Cp-99994 SCHEMBL14513344 | 0.93 | TACR1 (1.00) | TACR1CYP2D6 | |
| Cp-99994 SCHEMBL1282327 | 0.93 | TACR1 (1.00) | TACR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221151-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | HUMPHREY JOHN MICHAEL | 2008-09-11 | — | — | US | claimed |
| US-7381741-B2 | In which the amino is substituted by arylmethyl- or heteroarylmethyl- group, e.g., 2-Methoxybenzyl)-(2-phenylpyrrolidin-3-yl)-amine and 5-{[2-(3-Chloro-phenyl)-pyrrolidin-3-ylamino]-methyl}-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphalen-2-one; neurokinin 1 (Substance P) inhititors | PFIZER INC (US) | 2008-06-03 | — | — | US | claimed |
| EP-1753718-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2007-02-21 | — | — | EP | claimed |
| US-20050288358-A1 | 3-amino-2-phenylpyrrolidine derivatives | PFIZER INC. | 2005-12-29 | — | — | US | claimed |
| WO-2005115976-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| CN-1529600-A | Use of NK-1-receptor antagonists tomodify unwanted behavior indogs, casts and horses | �Ʒ� | 2004-09-15 | — | — | CN | claimed |
| EP-1411946-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS TO MODIFY UNWANTED BEHAVIOR IN DOGS, CATS AND HORSES | Pfizer Products Inc. (US) | 2004-04-28 | — | — | EP | claimed |
| EP-0721778-B1 | NK-1 receptor antagonists for the treatment of neuronal injury and stroke | PFIZER (US) | 2004-03-03 | — | — | EP | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| EP-0655246-A1 | Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria | PFIZER INC. (US) | 1995-05-31 | — | — | EP | claimed |
| EP-0653208-A2 | Pharmaceutical agents for treatment or prevention of sunburn | PFIZER INC. (US) | 1995-05-17 | — | — | EP | claimed |
| US-5393762-A | Pharmaceutical agents for treatment of emesis | PFIZER INC. (US) | 1995-02-28 | — | — | US | claimed |
| EP-0436334-B1 | 3-Aminopiperidine derivatives and related nitrogen containing heterocycles | PFIZER (US) | 1994-12-07 | — | — | EP | claimed |
| EP-0627221-A2 | Substance P antagonists for the treatment of emesis | PFIZER INC. (US) | 1994-12-07 | — | — | EP | claimed |
| US-5340826-A | Pharmaceutical agents for treatment of urinary incontinence | PFIZER INC. (US) | 1994-08-23 | — | — | US | claimed |
| EP-0610021-A1 | Pharmaceutical agents for treatment of urinary incontinence | PFIZER INC. (US) | 1994-08-10 | — | — | EP | claimed |
| US-5232929-A | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use | PFIZER INC. (US) | 1993-08-03 | — | — | US | claimed |
| WO-1991009844-A1 | SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1991-07-11 | — | — | WO | claimed |
| EP-0436334-A2 | 3-Aminopiperidine derivatives and related nitrogen containing heterocycles | PFIZER INC. (US) | 1991-07-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221151-A1 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES | PBK, KCND3, KCND2 | TACR1 33/4885KDM1A 1363/4885MAOA 3154/4885 |
| US-20050288358-A1 | 3-amino-2-phenylpyrrolidine derivatives | PBK, KCND3, KCND2 | TACR1 33/4885KDM1A 1363/4885MAOA 3154/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | TACR1 190/4885KDM1A 291/4885MAOA 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.